<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04132518</url>
  </required_header>
  <id_info>
    <org_study_id>43CHSA1803</org_study_id>
    <nct_id>NCT04132518</nct_id>
  </id_info>
  <brief_title>Sculptra for Correction of Midface Volume Deficit and/or Midface Contour Deficiency</brief_title>
  <official_title>A Randomized, Multi-center, Evaluator-blinded, No-treatment Controlled Study to Evaluate the Effectiveness and Safety of Sculptra for Correction of Midface Volume Deficit and/or Midface Contour Deficiency</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Q-Med AB</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Q-Med AB</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a randomized, evaluator-blinded, no-treatment controlled study in subjects with&#xD;
      Midface Volume Deficit and/or Midface Contour Deficiency.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      For Group A, after screening, eligible subjects will be treated from day 1 and followed up&#xD;
      for 24 months.&#xD;
&#xD;
      For Group B, the study includes two phases as follows:&#xD;
&#xD;
      Main study phase: It is randomized, evaluator-blinded and no-treatment controlled. After&#xD;
      screening, all eligible subjects will be randomized either to the Treatment Group or the&#xD;
      Control Group in a 2:1 ratio. All the subjects will be followed up for 12 months.&#xD;
&#xD;
      Extension study phase: After the main study phase, the Treatment Group will be followed up&#xD;
      for additional 12 months.&#xD;
&#xD;
      Each subject assigned to Group A and Treatment Group will receive up to 4 injection sessions&#xD;
      with 5(±1) weeks intervals.&#xD;
&#xD;
      Subjects assigned to the Control Group will not receive treatment during the study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">November 14, 2019</start_date>
  <completion_date type="Anticipated">April 30, 2022</completion_date>
  <primary_completion_date type="Anticipated">October 30, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Measure the percentage of responders</measure>
    <time_frame>12 month</time_frame>
    <description>Percentage of responders (defined by at least 1 point improvement on MMVS from baseline on both sides of the face) was measured by blinded evaluator at 12 months.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">213</enrollment>
  <condition>Midface Volume Deficit</condition>
  <arm_group>
    <arm_group_label>Treatment Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Each subject assigned to Treatment Group will receive up to 4 injection sessions with 5(±1) weeks intervals.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control Group</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Subjects assigned to the Control Group will not receive treatment during the study.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Sculptra</intervention_name>
    <description>Initial injection and optional 3 injections with Sculptra in Midface.</description>
    <arm_group_label>Treatment Group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Signed and dated informed consent to participate in the study.&#xD;
&#xD;
          2. Men or women aged 18 years of age or older of Chinese origin.&#xD;
&#xD;
          3. Subjects seeking augmentation therapy for the midface.&#xD;
&#xD;
          4. MMVS score of 2, 3 or 4 on each side of the face as assessed by the blinded evaluator.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Known/previous allergy or hypersensitivity to any of the constituents of the product.&#xD;
&#xD;
          2. Known/previous allergy or hypersensitivity to local anaesthetics, e.g. lidocaine or&#xD;
             other amide-type anaesthetics.&#xD;
&#xD;
          3. History of severe or multiple allergies, such as anaphylaxis.&#xD;
&#xD;
          4. Previous tissue revitalization treatment with laser or light, mesotherapy,&#xD;
             radiofrequency, ultrasound, cryotherapy, chemical peeling or dermabrasion in the area&#xD;
             to be treated within 6 months before treatment.&#xD;
&#xD;
          5. Previous surgery (including aesthetic facial surgical therapy or liposuction),&#xD;
             piercing or tattoo in the area to be treated.&#xD;
&#xD;
          6. Previous tissue augmentation therapy or contouring with any permanent&#xD;
             (non-biodegradable) or semi-permanent filler, autologous fat, lifting threads or&#xD;
             permanent implant in the area to be treated.&#xD;
&#xD;
          7. Other condition preventing the subject from entering the study in the Investigator's&#xD;
             opinion, e.g. subjects not likely to avoid other facial cosmetic treatments, subjects&#xD;
             anticipated to be unreliable, unavailable or incapable of understanding the study&#xD;
             assessments or having unrealistic expectations of the treatment result.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Xiongzheng Mu</last_name>
    <role>Principal Investigator</role>
    <affiliation>Huashan Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Huashan Hospital, Fudan Univesity</name>
      <address>
        <city>Shanghai</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>October 15, 2019</study_first_submitted>
  <study_first_submitted_qc>October 16, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">October 18, 2019</study_first_posted>
  <last_update_submitted>September 12, 2021</last_update_submitted>
  <last_update_submitted_qc>September 12, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 14, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>PLLA</keyword>
  <keyword>Midface Volume Deficit</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

